
Hyperparathyroidism - Pipeline Insight, 2024
Description
Hyperparathyroidism - Pipeline Insight, 2024
DelveInsight’s, “Hyperparathyroidism - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hyperparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hyperparathyroidism: Overview
Hyperparathyroidism is due to increased activity of the parathyroid glands, either from an intrinsic abnormal change altering excretion of parathyroid hormone (primary or tertiary hyperparathyroidism) or from an extrinsic abnormal change affecting calcium homoeostasis stimulating production of parathyroid hormone (secondary hyperparathyroidism).
The majority of primary hyperparathyroidism (PHPT) patients do not present with the classic symptoms of kidney stones or severe bone disease. Individuals are more often diagnosed today through routine biochemical laboratory testing done for other purposes. Most patients with PHPT have single adenomatous (80%) or multiply hyperplastic (15% to 20%) parathyroid tissue. Multiglandular disease can also be manifest as two and, very rarely, three adenomas. Parathyroid carcinoma is rare, accounting for <1% of all cases of PHPT (11). Suspicion for parathyroid cancer should be increased when patients, who are typically younger by about one decade, present with much higher serum calcium and PTH levels. Invariably, renal and skeletal involvement will be readily apparent.
""Hyperparathyroidism- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperparathyroidism pipeline landscape is provided which includes the disease overview and Hyperparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hyperparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Hyperparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve in Hyperparathyroidism.
- In June 2021, has received Marketing Authorization approval today for UPASITA® IV Injection Syringes (generic name: Upacicalcet Sodium Hydrate; ""UPASITA) for the treatment of secondary hyperparathyroidism in patients on hemodialysis.
- Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session.
Hyperparathyroidism Emerging Drugs
- VS-105: Vidasym
- MT-4580: Mitsubishi Tanabe Pharma
Further product details are provided in the report……..
Hyperparathyroidism: Therapeutic Assessment
This segment of the report provides insights about the different Hyperparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hyperparathyroidism
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Small Molecule
- Peptide
- Vitamin D analogues
- Molecule Type
- Intravenous
- Oral
- Subcutaneous
- Product Type
Hyperparathyroidism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperparathyroidism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperparathyroidism drugs.
Hyperparathyroidism Report Insights
- Hyperparathyroidism Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hyperparathyroidism drugs?
- How many Hyperparathyroidism drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperparathyroidism?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hyperparathyroidism therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hyperparathyroidism and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vidasym Inc.
- Mitsubishi Tanabe Pharma
- Shanghai Hengrui Pharmaceutical
- VS-105
- MT-4580
- SHR6508
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Hyperparathyroidism: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Hyperparathyroidism – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- MT-4580: Mitsubishi Tanabe Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- VS-105: Vidasym
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- SHR-6508: Shanghai Hengrui Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Hyperparathyroidism Key Companies
- Hyperparathyroidism Key Products
- Hyperparathyroidism- Unmet Needs
- Hyperparathyroidism- Market Drivers and Barriers
- Hyperparathyroidism- Future Perspectives and Conclusion
- Hyperparathyroidism Analyst Views
- Hyperparathyroidism Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.